RSV protection study for Brazilian infants
Part of Infections, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study looks at babies in Brazil who develop breathing or cold-like symptoms, to see how well the RSV vaccine given to mothers during pregnancy protects infants from severe RSV illness. If your baby is under 1 year old and has respiratory symptoms, they may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby was born in Brazil, and you lived in Brazil during the pregnancy.
- Your baby is 1 year old or younger (360 days or less) when the sample is taken.
- Your baby was born at 37 weeks of pregnancy or later (full term).
- Your baby has signs of a respiratory infection, like a runny nose, cough, or trouble breathing.
- You (the mother) received the RSV vaccine (like Abrysvo) during this pregnancy, at least 2 weeks before the baby's birth.
- Neither you nor your baby has received any other RSV prevention shot or medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
This study tests an RSV antibody shot that helps protect babies from severe RSV. It aims to see how well this preventive shot works in Aboriginal and Torres Strait Islander infants when given around 6-9 months of age.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This registry follows pregnant people who received an RSV vaccine during a specific window (32 to 36 weeks) to monitor safety. If you got the shot in that time, your information helps researchers understand how well the vaccine works in pregnancy.
This study tests a new vaccine that may protect babies from a common breathing virus called RSV. It is given to healthy women to see if it is safe and if it helps the body make protection that could be passed to a baby during pregnancy.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.